Zobrazeno 1 - 10
of 448
pro vyhledávání: ''
Autor:
Ashish Panigrahi, Constantine S. Tam, Piers Blombery, Xiangting Chen, John F. Seymour, Dennis A. Carney, Andrew H. Wei, Thomas E Lew, Mary Ann Anderson, Andrew W. Roberts, Ella R. Thompson, David C. S. Huang, Tamia Nguyen, David Westerman, Michael A. Dengler, Victor S Lin, Sasanka M. Handunnetti, Jerry M. Adams
Publikováno v:
Blood. 139:1198-1207
The BCL2 inhibitor venetoclax has established therapeutic roles in chronic lymphocytic leukemia (CLL) and acute myeloid leukemia (AML). As BCL2 is an important determinant of survival of both myeloid progenitor and B cells, we investigated whether cl
Autor:
Brian S. Gloss, Kavitha Gowrishankar, Piers Blombery, Raymond H. Y. Louie, Kenneth P. Micklethwaite, Emily Blyth, Fritz J. Sedlazeck, Janine Street, David Gottlieb, Matthew MacKay, Christopher E. Mason, David Bishop, Leili Moezzi, Gaurav Sutrave, Curtis Cai, Ziduo Li, Leighton Clancy, Fabio Luciani, Jonathan Foox, Melanie A Mach
Publikováno v:
Blood. 138:1391-1405
We performed a phase 1 clinical trial to evaluate outcomes in patients receiving donor-derived CD19-specific chimeric antigen receptor (CAR) T cells for B-cell malignancy that relapsed or persisted after matched related allogeneic hemopoietic stem ce
Autor:
John C. Byrd, Deborah M. Stephens
Publikováno v:
Blood
Bruton tyrosine kinase inhibitors (BTKi) have significantly changed the treatment landscape for patients with B-cell malignancies, including chronic lymphocytic leukemia, Waldenstrom macroglobulinemia, mantle cell lymphoma, and marginal zone lymphoma
Autor:
Laurence Kraus-Berthier, Lucie Laplane, Véronique Saada, Céline Berthon, Maria E. Figueroa, Bouchra Badaoui, Margaux Sevin, Franck Debeurme, Eric Padron, Thorsten Braun, Qin Yang, Nathalie Droin, Raphael Itzykson, Guido Kroemer, Dorothée Selimoglu-Buet, Eric Solary, Oliver Kepp, Margot Morabito, Alix Derreal, Hannah Newman, Sylvain Thepot, Gabriel Etienne, Miguel Torres-Martin, Sébastien Banquet, Severine Badel, Orianne Wagner-Ballon, Pierre Fenaux
Publikováno v:
Blood
Blood, American Society of Hematology, 2021, 137 (24), pp.3390-3402. ⟨10.1182/blood.2020008729⟩
Blood, American Society of Hematology, 2021, 137 (24), pp.3390-3402. ⟨10.1182/blood.2020008729⟩
Mouse models of chronic myeloid malignancies suggest that targeting mature cells of the malignant clone disrupts feedback loops that promote disease expansion. Here, we show that in chronic myelomonocytic leukemia (CMML), monocytes that accumulate in
Autor:
Hojoon Lee, Hanlee P. Ji, Michael S. Binkley, Grady Day, Sarah Haebe, Steven R. Long, Brock A. Martin, Ronald Levy, Debra K. Czerwinski, Susan M. Grimes, Tanaya Shree, Anuja Sathe
Publikováno v:
Blood. 137:2869-2880
Tumor heterogeneity complicates biomarker development and fosters drug resistance in solid malignancies. In lymphoma, our knowledge of site-to-site heterogeneity and its clinical implications is still limited. Here, we profiled 2 nodal, synchronously
Autor:
Tao Wang, Helen E. Heslop, Stephen Gottschalk, Bambi Grilley, Rammurti T. Kamble, Carlos A. Ramos, Ann M. Leen, Meng-Fen Wu, Malcolm K. Brenner, Robert A. Krance, Catherine Robertson, Manik Kuvalekar, Jasleen K. Randhawa, Spyridoula Vasileiou, Adrian P. Gee, Suhasini Lulla, Juan F. Vera, Betty Chung, Ayumi Watanabe, Premal Lulla, Ifigeneia Tzannou, Swati Naik, LaQuisa Hill, George Carrum
Publikováno v:
Blood
Relapse after allogeneic hematopoietic stem cell transplantation (HCT) is the leading cause of death in patients with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS). Infusion of unselected donor lymphocytes (DLIs) enhances the graft-v
Autor:
Ulrich Jaeger, Marek Borsky, Jan Oppelt, Laura Z. Rassenti, Medhat Shehata, Václav Šeda, Thomas J. Kipps, Gabriela Pavlasova, Jennifer R. Brown, Daniel Filip, Kvetoslava Liskova, Šárka Pospíšilová, Eva Vojackova, Lenka Kostalova, Matthew S. Davids, Marek Mráz, Katerina Cerna, Sonali Sharma, Jiri Mayer, Andrea Janíková, Pedro Faria Zeni, Stacey M. Fernandes, Veronika Šandová, Laura Ondrisova, Michael Doubek, Leos Kren
Publikováno v:
Blood
B-cell receptor (BCR) signaling and T-cell interactions play a pivotal role in chronic lymphocytic leukemia (CLL) pathogenesis and disease aggressiveness. CLL cells can use microRNAs (miRNAs) and their targets to modulate microenvironmental interacti
Autor:
Isabelle S. Csete, Ross L. Levine, Qi Gao, Alexander Chan, Andriy Derkach, Maximilian Stahl, Sheng F. Cai, Jinjuan Yao, Tanmay Mishra, Richard Koche, Sophia Yanis, Martin S. Tallman, Aaron D Goldberg, Michael R. Waarts, Raajit K. Rampal, Ahmet Dogan, Robert L. Bowman, Minal Patel, Ying Liu, Wenbin Xiao, Mikhail Roshal, Maria E. Arcila, Jeeyeon Baik, Nicole L. DelGaudio, Christopher Famulare, Yanming Zhang
Publikováno v:
Blood
Plasmacytoid dendritic cells (pDCs) are the principal natural type I interferon–producing dendritic cells. Neoplastic expansion of pDCs and pDC precursors leads to blastic plasmacytoid dendritic cell neoplasm (BPDCN), and clonal expansion of mature
Autor:
Gilad Itchaki, Svitlana Tyekucheva, Shuai Dong, Ignaty Leshchiner, Ishwarya Murali, Dimitri Livitz, Emily M. Thrash, Jasneet Kaur Khalsa, Amy J. Johnson, Gad Getz, Jennifer R. Brown, Stacey M. Fernandes, Siddha Kasar, Aishath S Naeem
Publikováno v:
Blood. 138:44-56
Inhibitors of Bruton tyrosine kinase (BTK) and phosphatidylinositol 3-kinase δ (PI3Kδ) that target the B-cell receptor (BCR) signaling pathway have revolutionized the treatment of chronic lymphocytic leukemia (CLL). Mutations associated with resist
Autor:
Hsin-An Hou, Amy L. Aldrich, Amy F McLemore, Susan Geyer, Eric Padron, Kathy L. McGraw, Abhishek Dhawan, Rami S. Komrokji, Sarah Warren, John L. Cleveland, Kyle J. MacBeth, Steffen Boettcher, Alan F. List, Benjamin L. Ebert, Amy Sullivan, Jeffrey E. Lancet, Erika A. Eksioglu, Manja Meggendorfer, Najla Al Ali, Torsten Haferlach, David A. Sallman
Publikováno v:
Blood. 136:2812-2823
Somatic gene mutations are key determinants of outcome in patients with myelodysplastic syndromes (MDS) and secondary AML (sAML). In particular, patients with TP53 mutations represent a distinct molecular cohort with uniformly poor prognosis. The pre